Targeting the PD-L1 cytoplasmic domain and its regulatory pathways to enhance cancer immunotherapy

扫码查看

原文链接

NETL
NSTL
万方数据

外文摘要：As a significant member of the immune checkpoint,programmed cell death 1 ligand 1(PD-L1)plays a critical role in cancer immune escape and has become an important target for cancer immunotherapy.Clinically approved drugs mainly target the extracellular domain of PD-L1.Recently,the small cytoplasmic domain of PD-L1 has been reported to regulate PD-L1 stability and function through multiple pathways.Therefore,the intracellular domain of PD-L1 and its regulatory pathways could be promising targets for cancer therapy,expanding available strategies for combined immunotherapy.Here,we summarize the emerging roles of the PD-L1 cytoplasmic domain and its regulatory pathways.The conserved motifs,homodimerization,and posttranslational modifica-tions of the PD-L1 cytoplasmic domain have been reported to regulate the membrane anchoring,degradation,nuclear translocation,and glycosylation of PD-L1.This summary provides a comprehensive understanding of the functions of the PD-L1 cytoplasmic domain and evaluates the broad prospects for targeted therapy.

外文关键词：

PD-L1cytoplasmic domainimmunotherapyposttranslational modification

作者：

Fangni Chai、Pan Li、Xin Liu、Zhihui Zhou、Haiyan Ren

展开 >

作者单位：

Division of Respiratory and Critical Care Medicine,West China Hospital of Sichuan University,Chengdu 610041,China

Collaborative Innovation Center of Biotherapy,Chengdu 610041,China

基金：

grants to H.R.from the National Key Research and Development Program of ChinaNational Natural Science Foundation of ChinaNational Natural Science Foundation of China1.3.5 project for disciplines of excellence,West China Hospital,Sichuan University

项目编号：

2018YFA01092003227131531872727ZYYC20020

出版年：

2023

DOI：

10.1093/jmcb/mjad070

分子细胞生物学报(英文版)

中国科学院上海生命科学研究院,生物化学与细胞生物学研究所,中国细胞生物学学会

分子细胞生物学报(英文版)

CSTPCDCSCD

影响因子：0.595

ISSN：1673-520X

年,卷(期)：2023.(11)

参考文献量70